{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:38:52Z","timestamp":1792737532646,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1583"],"award-info":[{"award-number":["SFB 1583"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DOK-184-20"],"award-info":[{"award-number":["DOK-184-20"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1583"],"award-info":[{"award-number":["SFB 1583"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["AZ-1365-18"],"award-info":[{"award-number":["AZ-1365-18"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["AZ-1365-18"],"award-info":[{"award-number":["AZ-1365-18"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) develops chemoresistance through dynamic cell-state transitions, yet the regulatory network architecture governing drug-tolerant states remains poorly characterised, because static expression snapshots cannot capture how interaction topology evolves along treatment-induced trajectories. We established a 3D PANC-1 tissue model on decellularised porcine intestinal matrix, which reaches patient-like proliferation indices and tissue-niche-specific drug responses, and performed single-cell RNA sequencing across four conditions: control, gemcitabine (GEM), TGF-\u03b21, and their combination. Coupling pseudotime trajectory inference to dynamic protein\u2013protein interaction network analysis, we tracked betweenness centrality continuously across cell-state transitions rather than comparing discrete states. GEM survivors engaged a proliferative programme (E2F1, CDK1, AURKA, TPX2, TOP2A, BIRC5), whereas TGF-\u03b21 induced an independent EMT attractor (SPOCK1, MBOAT2, COL5A1, THBS1, FN1). Where the two converged, an emergent bottleneck appeared: CDK1 betweenness centrality spiked selectively, restrained by CDKN1A (p21) and WEE1, defining an S-phase-persistence state enriched for GEM survivors. Cross-examination in a PDAC atlas of 726,107 cells from 231 patients showed 8.7-fold metastatic enrichment of triple-positive cells. This framework, linking controlled 3D tissue experimentation, single-cell systems analysis and clinical-scale patient data, is applicable to drug resistance across cancer types.<\/jats:p>","DOI":"10.1038\/s41540-026-00830-z","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:32:56Z","timestamp":1792729976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["3D tissue model to patient atlas: dynamic network topology reveals PDAC chemoresistance bottlenecks"],"prefix":"10.1038","volume":"12","author":[{"given":"Maryam","family":"Almasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-7049","authenticated-orcid":false,"given":"Jes\u00fas Guillermo","family":"Nieves Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-5794","authenticated-orcid":false,"given":"Gudrun","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Balkenhol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"830_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"830_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","volume":"36","author":"DPS Sohal","year":"2018","unstructured":"Sohal, D. P. S. et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 36, 2545\u20132556 (2018).","journal-title":"J. Clin. Oncol."},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein, A. N. et al. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272\u2013286 (2022).","journal-title":"Nat. Cancer"},{"key":"830_CR5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395\u20132406 (2018).","journal-title":"N. Engl. J. Med."},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy, T. et al. Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 8, 1571\u20131578 (2022).","journal-title":"JAMA Oncol."},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ijc.1351","volume":"93","author":"P Cappella","year":"2001","unstructured":"Cappella, P. et al. Cell cycle effects of Gemcitabine. Int. J. Cancer 93, 401\u2013408 (2001).","journal-title":"Int. J. Cancer"},{"key":"830_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L de Sousa Cavalcante","year":"2014","unstructured":"de Sousa Cavalcante, L. & Monteiro, G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741, 8\u201316 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/gut.2010.226092","volume":"60","author":"A Neesse","year":"2011","unstructured":"Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861\u2013868 (2011).","journal-title":"Gut"},{"key":"830_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","volume":"39","author":"EL Deer","year":"2010","unstructured":"Deer, E. L. et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425\u2013435 (2010).","journal-title":"Pancreas"},{"key":"830_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.prp.2016.06.001","volume":"212","author":"JK Striefler","year":"2016","unstructured":"Striefler, J. K. et al. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Pathol. Res. Pract. 212, 726\u2013734 (2016).","journal-title":"Pathol. Res. Pract."},{"key":"830_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/1878-0261.12323","volume":"12","author":"C G\u00f6ttlich","year":"2018","unstructured":"G\u00f6ttlich, C. et al. A combined tissue-engineered\/in silico signature tool patient stratification in lung cancer. Mol. Oncol. 12, 1264\u20131285 (2018).","journal-title":"Mol. Oncol."},{"key":"830_CR13","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3390\/cancers14092176","volume":"14","author":"M Peindl","year":"2022","unstructured":"Peindl, M. et al. EMT, stemness, and drug resistance in biological context: a 3D tumor tissue\/in silico platform for analysis of combinatorial treatment in NSCLC with aggressive KRAS-biomarker signatures. Cancers 14, 2176 (2022).","journal-title":"Cancers"},{"key":"830_CR14","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1016\/j.csbj.2025.10.032","volume":"27","author":"A Caliskan","year":"2025","unstructured":"Caliskan, A. et al. Mathematical strategies for predicting resistant subpopulations from scRNAseq data of a PANC-1 3D tissue model: Insight into gemcitabine resistance and TGFB1-induced invasion and EMT. Comput. Struct. Biotechnol. J. 27, 4476\u20134495 (2025).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"830_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1158\/1078-0432.CCR-24-2183","volume":"31","author":"IM Loveless","year":"2025","unstructured":"Loveless, I. M. et al. Human pancreatic cancer single-cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells. Clin. Cancer Res. 31, 756\u2013772 (2025).","journal-title":"Clin. Cancer Res."},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.21873\/invivo.12155","volume":"34","author":"D Namima","year":"2020","unstructured":"Namima, D. et al. The effect of Gemcitabine on cell cycle arrest and microRNA signatures in pancreatic cancer cells. In Vivo 34, 3195\u20133203 (2020).","journal-title":"In Vivo"},{"key":"830_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00194528","volume":"14","author":"DS Shewach","year":"1996","unstructured":"Shewach, D. S. & Lawrence, T. S. Gemcitabine and radiosensitization in human tumor cells. Invest. N. Drugs 14, 257\u2013263 (1996).","journal-title":"Invest. N. Drugs"},{"key":"830_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-8","volume":"8","author":"Y Wang","year":"2009","unstructured":"Wang, Y. et al. Centrosome-associated regulators of the G2\/M checkpoint as targets for cancer therapy. Mol. Cancer 8, 8 (2009).","journal-title":"Mol. Cancer"},{"key":"830_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc1526","volume":"5","author":"T Marumoto","year":"2005","unstructured":"Marumoto, T., Zhang, D. & Saya, H. Aurora-A\u2014a guardian of poles. Nat. Rev. Cancer 5, 42\u201350 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"830_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrc2964","volume":"10","author":"SMA Lens","year":"2010","unstructured":"Lens, S. M. A., Voest, E. E. & Medema, R. H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825\u2013841 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"830_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41416-023-02295-x","volume":"129","author":"M Guenther","year":"2023","unstructured":"Guenther, M. et al. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Br. J. Cancer 129, 175\u2013182 (2023).","journal-title":"Br. J. Cancer"},{"key":"830_CR22","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","volume":"64","author":"JD Davidson","year":"2004","unstructured":"Davidson, J. D. et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64, 3761\u20133766 (2004).","journal-title":"Cancer Res."},{"key":"830_CR23","first-page":"138","volume":"1776","author":"LP Jordheim","year":"2007","unstructured":"Jordheim, L. P. & Dumontet, C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776, 138\u2013159 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"830_CR24","doi-asserted-by":"publisher","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","volume":"133","author":"Y Zhan","year":"2021","unstructured":"Zhan, Y. et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed. Pharmacother. 133, 110996 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"830_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jcp.20634","volume":"208","author":"F Li","year":"2006","unstructured":"Li, F. & Ling, X. Survivin study: an update of \u201cwhat is the next wave\u201d? J. Cell. Physiol. 208, 476\u2013486 (2006).","journal-title":"J. Cell. Physiol."},{"key":"830_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jss.2012.05.065","volume":"178","author":"S Kagawa","year":"2012","unstructured":"Kagawa, S. et al. Akt\/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J. Surg. Res. 178, 758\u2013767 (2012).","journal-title":"J. Surg. Res."},{"key":"830_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07077-8","volume":"15","author":"B Son","year":"2024","unstructured":"Son, B. et al. Targeted therapy of cancer stem cells: inhibition of mTOR in preclinical and clinical research. Cell Death Dis. 15, 696 (2024).","journal-title":"Cell Death Dis."},{"key":"830_CR28","doi-asserted-by":"publisher","first-page":"109934","DOI":"10.1016\/j.cellsig.2021.109934","volume":"81","author":"MA Chawsheen","year":"2021","unstructured":"Chawsheen, M. A. & Dash, P. R. mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism. Cell. Signal. 81, 109934 (2021).","journal-title":"Cell. Signal."},{"key":"830_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang, Q., Bode, A. M. & Zhang, T. Targeting CDK1 in cancer: mechanisms and implications. npj Precis. Oncol. 7, 58 (2023).","journal-title":"npj Precis. Oncol."},{"key":"830_CR30","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1042\/CS20180010","volume":"132","author":"P Chen","year":"2018","unstructured":"Chen, P. et al. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. Clin. Sci. 132, 1417\u20131433 (2018).","journal-title":"Clin. Sci."},{"key":"830_CR31","doi-asserted-by":"publisher","first-page":"651882","DOI":"10.3389\/fgene.2021.651882","volume":"12","author":"G Chen","year":"2021","unstructured":"Chen, G. et al. PLAU promotes cell proliferation and epithelial\u2013mesenchymal transition in head and neck squamous cell carcinoma. Front. Genet. 12, 651882 (2021).","journal-title":"Front. Genet."},{"key":"830_CR32","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1158\/0008-5472.CAN-07-0440","volume":"67","author":"PC Mahon","year":"2007","unstructured":"Mahon, P. C. et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 67, 6786\u20136795 (2007).","journal-title":"Cancer Res."},{"key":"830_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2020.11.013","volume":"501","author":"CPR Xavier","year":"2021","unstructured":"Xavier, C. P. R. et al. Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to Gemcitabine. Cancer Lett. 501, 210\u2013223 (2021).","journal-title":"Cancer Lett."},{"key":"830_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06729-z","volume":"15","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA. Cell Death Dis. 15, 340 (2024).","journal-title":"Cell Death Dis."},{"key":"830_CR35","first-page":"4269733","volume":"2022","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Identification of MBOAT2 as an unfavorable biomarker correlated with KRAS activation and reduced CD8+ T-cell infiltration in pancreatic cancer. J. Oncol. 2022, 4269733 (2022).","journal-title":"J. Oncol."},{"key":"830_CR36","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.3902","volume":"21","author":"S Lovisa","year":"2015","unstructured":"Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998\u20131009 (2015).","journal-title":"Nat. Med."},{"key":"830_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01793-z","volume":"22","author":"A Akhmetkaliyev","year":"2023","unstructured":"Akhmetkaliyev, A., Alibrahim, N., Shafiee, D. & Tulchinsky, E. EMT\/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin? Mol. Cancer 22, 90 (2023).","journal-title":"Mol. Cancer"},{"key":"830_CR38","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer 119, 1208\u20131214 (2018).","journal-title":"Br. J. Cancer"},{"key":"830_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.244","volume":"8","author":"J Musa","year":"2017","unstructured":"Musa, J., Aynaud, M. M., Mirabeau, O., Delattre, O. & Gr\u00fcnewald, T. G. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 8, e2895 https:\/\/doi.org\/10.1038\/cddis.2017.244 (2017).","journal-title":"Cell Death Dis."},{"key":"830_CR40","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1073\/pnas.92.12.5545","volume":"92","author":"MB Datto","year":"1995","unstructured":"Datto, M. B. et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92, 5545\u20135549 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"830_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","volume":"616","author":"M Debaugnies","year":"2023","unstructured":"Debaugnies, M. et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature 616, 168\u2013175 (2023).","journal-title":"Nature"},{"key":"830_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2023.11.009","volume":"97","author":"H Schuhwerk","year":"2023","unstructured":"Schuhwerk, H. & Brabletz, T. Mutual regulation of TGF\u03b2-induced oncogenic EMT, cell cycle progression and the DDR. Semin. Cancer Biol. 97, 86\u2013103 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"830_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba, G. et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14, 797 (2023).","journal-title":"Nat. Commun."},{"key":"830_CR44","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/15384101.2016.1148841","volume":"15","author":"LA Parsels","year":"2016","unstructured":"Parsels, L. A. et al. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle 15, 730\u2013739 (2016).","journal-title":"Cell Cycle"},{"key":"830_CR45","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: targeting ATR in cancer therapy. Clin. Cancer Res. 21, 4780\u20134785 (2015).","journal-title":"Clin. Cancer Res."},{"key":"830_CR46","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo, K. C. et al. Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J. Clin. Oncol. 37, 2643\u20132650 (2019).","journal-title":"J. Clin. Oncol."},{"key":"830_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","volume":"29","author":"R Jones","year":"2023","unstructured":"Jones, R. et al. A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clin. Cancer Res. 29, 331\u2013340 (2023).","journal-title":"Clin. Cancer Res."},{"key":"830_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero, B. et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell 37, 340\u2013353 (2020).","journal-title":"Cancer Cell"},{"key":"830_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg, J. F. et al. Stat3 as an oncogene. Cell 98, 295\u2013303 (1999).","journal-title":"Cell"},{"key":"830_CR50","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1089\/ten.2006.0388","volume":"13","author":"K Linke","year":"2007","unstructured":"Linke, K. et al. Engineered liver-like tissue on a capillarized matrix for applied research. Tissue Eng. 13, 2699\u20132707 (2007).","journal-title":"Tissue Eng."},{"key":"830_CR51","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/s41418-021-00823-x","volume":"28","author":"S Uxa","year":"2021","unstructured":"Uxa, S. et al. Ki-67 gene expression. Cell Death Differ. 28, 3357\u20133370 (2021).","journal-title":"Cell Death Differ."},{"key":"830_CR52","unstructured":"10x Genomics. Cell Ranger User Guide. https:\/\/www.10xgenomics.com\/support\/software\/cell-ranger\/latest (2024)."},{"key":"830_CR53","unstructured":"10x Genomics. Single-cell gene expression software pipelines: choosing a pipeline. https:\/\/www.10xgenomics.com\/support\/software\/cell-ranger\/latest\/analysis\/running-pipelines\/cr-choosing-a-pipeline (2024)."},{"key":"830_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.25080\/Majora-92bf1922-00a","volume":"51","author":"W McKinney","year":"2010","unstructured":"McKinney, W. Data structures for statistical computing in Python. Proc. 9th Python Sci. Conf. 51, 56 (2010).","journal-title":"Proc. 9th Python Sci. Conf."},{"key":"830_CR55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"830_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"830_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0953-9","volume":"17","author":"J Xin","year":"2016","unstructured":"Xin, J. et al. High-performance web services for querying gene and variant annotation. Genome Biol. 17, 91 (2016).","journal-title":"Genome Biol."},{"key":"830_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291 (2019).","journal-title":"Cell Syst."},{"key":"830_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","volume":"585","author":"CR Harris","year":"2020","unstructured":"Harris, C. R. et al. Array programming with NumPy. Nature 585, 357\u2013362 (2020).","journal-title":"Nature"},{"key":"830_CR60","doi-asserted-by":"crossref","unstructured":"McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at https:\/\/arxiv.org\/abs\/1802.03426 (2018).","DOI":"10.21105\/joss.00861"},{"key":"830_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41695-z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019).","journal-title":"Sci. Rep."},{"key":"830_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 https:\/\/doi.org\/10.1093\/bioinformatics\/btac757 (2023).","journal-title":"Bioinformatics"},{"key":"830_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac746","volume":"39","author":"L Faure","year":"2023","unstructured":"Faure, L., Soldatov, R., Kharchenko, P. V. & Adameyko, I. scFates: a scalable Python package for advanced pseudotime and bifurcation analysis from single-cell data. Bioinformatics 39, btac746 https:\/\/doi.org\/10.1093\/bioinformatics\/btac746 (2023).","journal-title":"Bioinformatics"},{"key":"830_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41587-019-0068-4","volume":"37","author":"M Setty","year":"2019","unstructured":"Setty, M. et al. Characterization of cell fate probabilities in single-cell data with Palantir. Nat. Biotechnol. 37, 451\u2013460 (2019).","journal-title":"Nat. Biotechnol."},{"key":"830_CR65","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation 5, 100625 (2024).","journal-title":"Innovation"},{"key":"830_CR66","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br. J. Pharmacol. 181, 362\u2013374 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"830_CR67","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/nmeth.4077","volume":"13","author":"D T\u00fcrei","year":"2016","unstructured":"T\u00fcrei, D., Korcsm\u00e1ros, T. & Saez-Rodriguez, J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. Nat. Methods 13, 966\u2013967 (2016).","journal-title":"Nat. Methods"},{"key":"830_CR68","unstructured":"Csardi, G. & Nepusz, T. The igraph software package for complex network research. InterJournal Complex Syst. 1695 (2006)."},{"key":"830_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fpls.2016.00444","volume":"7","author":"EAR Serin","year":"2016","unstructured":"Serin, E. A. R., Nijveen, H., Hilhorst, H. W. M. & Ligterink, W. Learning from co-expression networks: possibilities and challenges. Front. Plant Sci. 7, 444 (2016).","journal-title":"Front. Plant Sci."},{"key":"830_CR70","doi-asserted-by":"publisher","unstructured":"Loveless, I. M. & Steele, N. G. Single Cell RNAseq Pancreatic Cancer Atlas. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14199536 (2024).","DOI":"10.5281\/zenodo.14199536"},{"key":"830_CR71","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41587-019-0336-3","volume":"37","author":"KR Moon","year":"2019","unstructured":"Moon, K. R. et al. Visualizing structure and transitions in high-dimensional biological data. Nat. Biotechnol. 37, 1482\u20131492 (2019).","journal-title":"Nat. Biotechnol."},{"key":"830_CR72","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","volume":"56","author":"AM Khaliq","year":"2024","unstructured":"Khaliq, A. M. et al. Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity. Nat. Genet. 56, 2455\u20132465 (2024).","journal-title":"Nat. Genet."},{"key":"830_CR73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"830_CR74","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"M Waskom","year":"2021","unstructured":"Waskom, M. seaborn: statistical data visualization. J. Open Source Softw. 6, 3021 (2021).","journal-title":"J. Open Source Softw."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00830-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:23Z","timestamp":1792735343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1038\/s41540-026-00830-z","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"158"}}